Is Covid a thing of the past? Flu is back to being the most common winter ailment

U.S. flu activity has outpaced Covid this winter with an estimated 25 million flu infections since October versus 3–9 million Covid infections; hospitalizations are at least ~330,000 for flu and 96,000–170,000 for Covid, and estimated deaths are roughly 10,000–30,000 for flu versus ~20,000 for Covid. While experts characterize Covid as endemic with generally milder disease and vaccines reducing severe outcomes, falling vaccine uptake among older adults (down 9%) and recent U.S. policy moves to halt pandemic-related contracts and limit recommendations raise preparedness and public-health funding risks that could affect healthcare demand, insurer exposure and labor supply if trends reverse.

Analysis

Market structure: A durable shift toward flu dominance vs. Covid in the U.S. favors incumbents in seasonal-vaccine and diagnostics markets (GSK, SNY, ABT, QDEL) while compressing demand and pricing power for Covid-specific vaccine makers (MRNA, BNTX) and pandemic-era testing pure-plays. Lower Covid vaccination rates and halted government procurement create a demand shock (volumes down high-single digits to double digits year-over-year) and inventory risk for Covid vaccine suppliers, while hospitals/insurers face higher winter bed utilization but lower ICU intensity.

Risk assessment: Key tail risks are emergence of a materially immune‑evasive Covid variant (low probability, high impact) and further federal budget cuts to pandemic preparedness; either would reprice vaccine and biotech equities within 7–90 days. Near-term (days–weeks) sensitivity centers on CDC/WHO guidance and flu-variant reports; medium-term (3–12 months) depends on fiscal appropriations and contract awards; long-term (1–3 years) is structural endemicity and recurring seasonal vaccine cycles.

Trade implications: Favor selective longs in large-cap flu vaccine makers and diversified diagnostics (3–6 month window), avoid or hedge pure-play Covid vaccine exposure, and prefer hospital operators with pricing power (HCA) over outpatient-testing chains with secular decline. Use options to express skewed risk: buy puts on names sensitive to procurement cuts and call or spread exposure to high-quality diagnostics.

Contrarian angles: Consensus underestimates balance‑sheet and contract risks at mRNA-first developers: the market may be underpricing a 20–40% downside if federal contracts are terminated. Conversely, flu incumbents are likely underappreciated winners given recurring annual demand and lower development timelines; historical parallels (post‑H1N1 demand normalization) suggest a 6–18 month re-rating opportunity for diversified vaccine makers.

Key Decisions for Investors

• Establish a 2–3% long position in GSK (GSK) or Sanofi (SNY) over the next 3–6 months to capture persistent flu vaccine demand; target 12–20% upside, set a 7–8% stop-loss, trim if WHO/CDC signals materially milder season in 60 days.
• Allocate 0.8–1.5% portfolio to long diagnostics: buy Abbott (ABT) 3–6 month call spread (e.g., 1x 6-month 5–10% ITM call / sell higher strike) to play sustained testing and hospital utilization; look for 15–25% realized upside if winter admissions remain elevated.
• Establish a 1% short or hedge on Moderna (MRNA) via buying 6-month 20% OTM puts (or put spread) to protect vs. inventory/contract risk; if HHS awards new large-scale contracts within 30–60 days, close hedge; otherwise increase size to 2% on confirmed procurement cancellations.
• Reduce exposure to pure-play Covid vaccine developers and testing chains by 30–50% if U.S. federal procurement spend announcements in the next 30–90 days show >20% year-over-year cuts; redeploy proceeds into GSK/SNY and ABT or short MRNA as above.